What is the Anti-HAV Seroprevalence of Travelers >60 Years or Having Lived in a Tropical Country for >5 Years

NCT04638335 | Completed

• 1 other identifier: AHAV-UNIL
• Study Type: observational
• Target: 50
• Locations: 1 country
• Sites: 1

Brief Summary

Study to determine the proportion of travelers over the age of 60 years and travelers having lived in a tropical country for more than 5 years with anti-HAV antibodies. This will be done through a blood test. The investigators will then proceed with a short statistical analysis.

Conditions

Hepatitis A

Outcome Measures

Primary Outcomes (1)

• the percentage of anti-HAV positive tests in the two groups will be calculated

  In the first groupe, the percentage of travelers over 60 years of age with a positive anti-HAV test will be calculated. In the second groupe, the percentage of travelers having lived for more than 5 years in a tropical country with a positive anti-HAV test will be calculated.

  through study completion, an average of 1 year

Study Arms (2)

travelers over the age of 60

blood sample taken to test the presence of Anti-HAV antibodies

Biological: Blood test

travelers having lived in a tropical country for more than 5 years

blood sample taken to test the presence of Anti-HAV antibodies

Biological: Blood test

Interventions

Blood test BIOLOGICAL

blood test for Anti-HAV antibodies

travelers having lived in a tropical country for more than 5 years; travelers over the age of 60

Eligibility Criteria

• Age: 5 Years+
• Sex: all
• Healthy Volunteers: Yes
• Age Groups: Child (0-17), Adult (18-64), Older Adult (65+)
• Sampling Method: Non-Probability Sample

Study Population

travelers coming for a consultation at the Policlinique de Médecine Tropicale, voyages et vaccinations, Unisanté

You may qualify if:

• people over 60 years old or travelers that have lived in a tropical country for at least 5 years who consult the travel clinic of Unisanté

You may not qualify if:

• subjects who have not given their consent,
• are younger than 5 years old,
• are unable to participate for some reason,
• have already been vaccinated against hepatitis A
• have been injected with immunoglobulins in the past 2 months (half-life of GamaStan: 23 days)

Sponsors & Collaborators

• University of Lausanne Hospitals: lead

Study Sites (1)

Travel Clinic, Department of Ambulatory Care and Community Medicine, University Hospital of Lausanne, Switzerland

Lausanne, Canton of Vaud, 1011, Switzerland

Location

Biospecimen

Retention: SAMPLES WITHOUT DNA

Blood

MeSH Terms

Conditions

Hepatitis A

Interventions

Hematologic Tests

Condition Hierarchy (Ancestors)

Hepatitis, Viral, Human; Virus Diseases; Infections; Enterovirus Infections; Picornaviridae Infections; RNA Virus Infections; Hepatitis; Liver Diseases; Digestive System Diseases

Intervention Hierarchy (Ancestors)

Clinical Laboratory Techniques; Diagnostic Techniques and Procedures; Diagnosis; Investigative Techniques

Study Officials

• Serge De vallière, MD,MSc

  Unisanté

  PRINCIPAL INVESTIGATOR

Study Design

• Study Type: observational
• Observational Model: COHORT
• Time Perspective: CROSS SECTIONAL
• Sponsor Type: OTHER
• Responsible Party: PRINCIPAL INVESTIGATOR
• PI Title: Principal Investigator

Study Record Dates

• First Submitted: October 25, 2020
• First Posted: November 20, 2020
• Study Start: October 6, 2019
• Primary Completion: December 31, 2021
• Study Completion: March 31, 2022
• Last Updated: August 23, 2022

Record last verified: 2022-08

Data Sharing

• IPD Sharing: Will share
• Shared Documents: STUDY PROTOCOL, SAP, CSR, ANALYTIC CODE
• Time Frame: The data will be shared within the year of completing the project and will be available for 2 years after first published.

Locations

CH (1)